Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Anaptysbio Inc (NQ: ANAB ) 24.61 -0.45 (-1.80%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 191,145 Open 25.00 Bid (Size) 15.00 (1) Ask (Size) 40.12 (2) Prev. Close 25.06 Today's Range 24.40 - 25.33 52wk Range 13.36 - 27.50 Shares Outstanding 27,433,359 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News The Analyst Landscape: 7 Takes On AnaptysBio May 10, 2024 Via Benzinga ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024 May 09, 2024 ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. Via InvestorPlace Performance YTD +13.41% +13.41% 1 Month +2.80% +2.80% 3 Month +15.43% +15.43% 6 Month +13.41% +13.41% 1 Year +25.43% +25.43% More News Read More Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) May 09, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties May 09, 2024 From AnaptysBio, Inc. Via GlobeNewswire Unveiling 4 Analyst Insights On AnaptysBio April 01, 2024 Via Benzinga BTIG Research Predicts Over 118% Rally for These 3 Stocks April 15, 2024 Via InvestorPlace Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week April 12, 2024 Via The Motley Fool Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session April 11, 2024 Via Benzinga Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday April 11, 2024 Via Benzinga Topics Stocks Exposures US Equities Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers March 12, 2024 Via Benzinga Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 11, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting February 29, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference January 31, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals November 27, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Named a BioSpace 2024 Best Places to Work Winner November 07, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update November 02, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Announces Participation in November Investor Conferences November 01, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress October 11, 2023 From AnaptysBio, Inc. Via GlobeNewswire Why Is Skin Disease Focused AnaptysBio Stock Trading Higher Today? October 09, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session October 09, 2023 Via Benzinga Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25 October 09, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) October 09, 2023 From AnaptysBio, Inc. Via GlobeNewswire Argenx's 28% Surge & Promising Product Propel Investor Confidence September 25, 2023 Via MarketBeat AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors September 18, 2023 From AnaptysBio, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
